Androgen Deprivation Therapy and Future Alzheimer's Disease Risk.

PURPOSE To test the association of androgen deprivation therapy (ADT) in the treatment of prostate cancer with subsequent Alzheimer's disease risk. METHODS We used a previously validated and implemented text-processing pipeline to analyze electronic medical record data in a retrospective cohort of patients at Stanford University and Mt. Sinai hospitals. Specifically, we extracted International Classification of Diseases-9th revision diagnosis and Current Procedural Terminology codes, medication lists, and positive-present mentions of drug and disease concepts from all clinical notes. We then tested the effect of ADT on risk of Alzheimer's disease using 1:5 propensity score-matched and traditional multivariable-adjusted Cox proportional hazards models. The duration of ADT use was also tested for association with Alzheimer's disease risk. RESULTS There were 16,888 individuals with prostate cancer meeting all inclusion and exclusion criteria, with 2,397 (14.2%) receiving ADT during a median follow-up period of 2.7 years (interquartile range, 1.0-5.4 years). Propensity score-matched analysis (hazard ratio, 1.88; 95% CI, 1.10 to 3.20; P = .021) and traditional multivariable-adjusted Cox regression analysis (hazard ratio, 1.66; 95% CI, 1.05 to 2.64; P = .031) both supported a statistically significant association between ADT use and Alzheimer's disease risk. We also observed a statistically significant increased risk of Alzheimer's disease with increasing duration of ADT (P = .016). CONCLUSION Our results support an association between the use of ADT in the treatment of prostate cancer and an increased risk of Alzheimer's disease in a general population cohort. This study demonstrates the utility of novel methods to analyze electronic medical record data to generate practice-based evidence.

[1]  N. Shah,et al.  Profiling risk factors for chronic uveitis in juvenile idiopathic arthritis: a new model for EHR-based research , 2013, Pediatric Rheumatology.

[2]  Jim C Hu,et al.  Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. , 2012, European urology.

[3]  Andrew J. Saykin,et al.  Candidate mechanisms for chemotherapy-induced cognitive changes , 2007, Nature Reviews Cancer.

[4]  P. Cheung,et al.  Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. , 2008, The Journal of urology.

[5]  Nigam H. Shah,et al.  Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population , 2015, PloS one.

[6]  D. Grobbee,et al.  Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. , 2010, International journal of epidemiology.

[7]  N. Shah,et al.  Pharmacovigilance Using Clinical Notes , 2013, Clinical pharmacology and therapeutics.

[8]  A. Rosenkrantz,et al.  Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification. , 2015, The Journal of urology.

[9]  A. Kibel.  Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer , 2007 .

[10]  A. Smith,et al.  Serum total testosterone is lower in men with Alzheimer's disease. , 2001, Neuro endocrinology letters.

[11]  Constantine Lyketsos,et al.  Dementia and Alzheimer's Disease Incidence in Relationship to Cardiovascular Disease in the Cardiovascular Health Study Cohort , 2005, Journal of the American Geriatrics Society.

[12]  C. Pike,et al.  Gender, sex steroid hormones, and Alzheimer's disease , 2013, Hormones and Behavior.

[13]  Pingkun Yan,et al.  Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. , 2011, The Journal of urology.

[14]  W. Kukull,et al.  Dementia epidemiology. , 2002, The Medical clinics of North America.

[15]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[16]  Julie S Snowden,et al.  The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. , 2011, Brain : a journal of neurology.

[17]  R. Mayeux,et al.  Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. , 2001, American journal of epidemiology.

[18]  J. Goodwin,et al.  Risk of fracture after androgen deprivation for prostate cancer. , 2005, The New England journal of medicine.

[19]  S. Basaria,et al.  Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. , 2008, The Journal of clinical endocrinology and metabolism.

[20]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[21]  A. D'Amico,et al.  Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. , 2007, Journal of the National Cancer Institute.

[22]  F. Beuvon,et al.  Detection of significant prostate cancer with magnetic resonance targeted biopsies--should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care? , 2015, The Journal of urology.

[23]  C. Lawton.  Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer , 2012 .

[24]  Deborah K. Padgett,et al.  Data Analysis and Interpretation , 2012 .

[25]  Elizabeth A Stuart,et al.  Matching methods for causal inference: A review and a look forward. , 2010, Statistical science : a review journal of the Institute of Mathematical Statistics.

[26]  R. Morton,et al.  Racial differences in adenocarcinoma of the prostate in North American men. , 1994, Urology.

[27]  A. Smith,et al.  Low free testosterone is an independent risk factor for Alzheimer's disease , 2004, Experimental Gerontology.

[28]  Austin B Frakt.  An observational study goes where randomized clinical trials have not. , 2015, JAMA.

[29]  W. J. Morris,et al.  Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma , 2002, Cancer.

[30]  G. Jackson,et al.  Low Testosterone Associated With Obesity and the Metabolic Syndrome Contributes to Sexual Dysfunction and Cardiovascular Disease Risk in Men With Type 2 Diabetes , 2011, Diabetes Care.

[31]  Wendy W. Chapman,et al.  ConText: An algorithm for determining negation, experiencer, and temporal status from clinical reports , 2009, J. Biomed. Informatics.

[32]  A. Hofman,et al.  Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study , 1997, The Lancet.

[33]  V. Shavers,et al.  Racial and ethnic disparities in the receipt of cancer treatment. , 2002, Journal of the National Cancer Institute.

[34]  J. Goodwin,et al.  Increasing use of gonadotropin‐releasing hormone agonists for the treatment of localized prostate carcinoma , 2005, Cancer.

[35]  Bethany Percha,et al.  Functional evaluation of out-of-the-box text-mining tools for data-mining tasks , 2014, J. Am. Medical Informatics Assoc..

[36]  Cui Tao,et al.  Unified Medical Language System term occurrences in clinical notes: a large-scale corpus analysis , 2012, J. Am. Medical Informatics Assoc..

[37]  C. Pike,et al.  Age-related testosterone depletion and the development of Alzheimer disease. , 2004, JAMA.

[38]  Nigam H. Shah,et al.  Practice-Based Evidence: Profiling the Safety of Cilostazol by Text-Mining of Clinical Notes , 2013, PloS one.

[39]  R. Martins,et al.  Chemical andropause and amyloid-beta peptide. , 2001, JAMA.

[40]  H. Jim,et al.  Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis , 2014, Supportive Care in Cancer.

[41]  Baris Turkbey,et al.  Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy. , 2014, The Journal of urology.

[42]  S. Resnick,et al.  Free testosterone and risk for Alzheimer disease in older men , 2004, Neurology.

[43]  C. Nelson,et al.  Cognitive effects of hormone therapy in men with prostate cancer , 2008, Cancer.

[44]  S. Asthana,et al.  Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment , 2005, Neurology.